Carbidopa and L-dopa prodrugs and methods of use

US9446059B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Benoit Cardinal-David · Chicago, US
• Vincent S. Chan · Evanston, US
• Kassibla E. Dempah · San Francisco, US
• Brian P. Enright · Gurnee, US
• Rodger F. Henry · Park City, US
• Raimundo Ho · Glenview, US
• Ye Huang · Gurnee, US
• Alexander D. Huters · Chicago, US
• Russell C. Klix · Buffalo Grove, US
• Scott W. Krabbe · Lindenhurst, US
• Philip R. Kym · Libertyville, US
• Yanbin Lao · Libertyville, US
• Xiaochun Lou · Long Grove, US
• Sean E. Mackey · Sunnyvale, US
• Mark A. Matulenko · Libertyville, US
• Peter T. Mayer · Libertyville, US
• Christopher P. Miller · Lake Forest, US
• James Stambuli · Worcester, US
• Eric A. Voight · Pleasant Prairie, US
• Zhi Wang · Philadelphia, US
• Geoff G. Zhang · Vernon Hills, US
• Valentino J. Stella · Lawrence, US

Key dates

• Filing date: Oct 21, 2015
• Grant date: Sep 20, 2016
• Expiry date: Oct 21, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.